Back to Agenda
From Breakthrough to Life: Engineered T-Cells, Patients, and the Future of Biotech
Session Chair(s)
Katie Truong
SVP & Managing Director, DIA Americas and Global Head of Business Operations
DIA, United States
Following a keynote presentation by Bruce Levine on the future of genetically engineered T-cells for human therapeutics, sit down with Bruce and Brad Watts for a fireside chat. Through scientific, policy, and patient lenses, the session will examine what it takes to translate high-risk science into sustainable therapies, and what that implies for regulators, payers, sponsors, and technology partners.
Learning Objective : Describe how advances in engineered T-cells, including CAR-T, are reshaping expectations for cancer treatment and the broader pipeline; Identify scientific, regulatory, and system conditions needed to translate high-risk engineered innovations into equitable, scalable patient benefit; Discuss how real patient and family experiences inform future strategies for regulators, payers, sponsors, researchers, and technology partners developing next-generation cell therapies.
Speaker(s)
Plenary Presenter
Bruce Levine
Perelman School of Medicine at the University of Pennsylvania, United States
Barabara and Edward Netter Professor in Cancer Gene Therapy
Panelist
Bradley Watts
Connor, Strong, and Buckelew, United States
Vice President, Business Development Executive
Have an account?